The Competition Commission of India approved Piramal Enterprises’ $16.5 million purchase four brands of pharmaceuticals from Pfizer Ltd.
The acquisition was announced in May and includes the brands of Ferradol, Neko, Sloan’s and Waterbury’s Compound as well as trademark rights for Ferradol and Waterbury’s Compound in Bangladesh and Sri Lanka.
Full Content: The Economic Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uber Faces Regulatory Heat as FTC Targets Subscription Practices
Apr 21, 2025 by
CPI
Supreme Court Declines to Hear CSX Antitrust Case Against Norfolk Southern
Apr 21, 2025 by
CPI
Proposed Antitrust Law Could Cost NY Billions, Says Business Council
Apr 21, 2025 by
CPI
India’s Antitrust Watchdog Clears Google Settlement in Android TV Case
Apr 21, 2025 by
CPI
Former DOJ Antitrust Leader Joins BakerHostetler as Partner in Washington Office
Apr 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickinson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece